CRISPR Therapeutics AG（CRSP）今日盘中股价大幅上涨5.61%，引起市场关注。
消息面上，基因编辑领域迎来重大利好。同业公司英特利亚疗法（Intellia Therapeutics）宣布，其用于治疗罕见水肿疾病的CRISPR基因编辑疗法在三期临床试验中达到主要终点，成为全球首款针对活体体内（in vivo）CRISPR基因编辑且获得三期临床阳性数据的疗法，标志着该技术领域的一个重要里程碑。该公司已启动向美国FDA的滚动式上市申请。这一积极进展提振了投资者对整个CRISPR基因编辑行业的信心，可能带动了包括CRISPR Therapeutics在内的相关公司股价上扬。
目前，FDA唯一获批的CRISPR药物是由福泰制药（Vertex）研发的体外（ex vivo）编辑疗法Casgevy。英特利亚疗法的体内编辑路径与之不同，其试验数据显示疗法安全性和耐受性表现良好，且长期随访中未出现疗效衰退案例，这进一步强化了市场对CRISPR技术临床应用前景的乐观预期。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.